Assessment of adherence to atovaquone-proguanil prophylaxis in travelers.
BACKGROUND
Malaria continues to be a serious, world-wide infection. Atovaquone-proguanil is one of the prophylactic agents recommended for travelers to endemic regions. However, little information is available regarding adherence with this medication. A large proportion of malaria cases reported from travelers is due to non-adherence to prescribed regimens. This study was undertaken to analyze adherence with atovaquone-proguanil prophylaxis and specific factors contributing to non-adherence.


METHODS
Men and non-pregnant women > or = 18 years of age were eligible for inclusion. Enrolled travelers received a prescription for atovaquone-proguanil prophylaxis and were contacted by telephone within 3 weeks of return to the United States. A questionnaire was prepared by the authors to determine if subjects were adherent with the medication. Additional data included demographics, duration of malarious travel, previous use of prophylactic agents, underlying medical conditions, concurrent medications, and reasons for non-adherence.


RESULTS
Complete data were available for 104/124 (84%) participants: 49 (47%) men, 55 (53%) women. Average duration of malarious travel was 12 days, and 19 (18%) travelers reported previous travel to a malarious region. Ninety-two (89%) subjects were completely adherent with their prophylactic atovaquone-proguanil course. Adverse effects were seen in 6 (5%) travelers.


CONCLUSIONS
Adherence with atovaquone-proguanil malaria prophylaxis is high among travelers from a non-endemic region. Adverse effects are minimal. Non-adherence was primarily attributable to travelers' perception of need.
DePetrillo
John C
JC
Division of Infectious Diseases, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA. jdepetrillo@nshs.edu
Singer
Carol
C
Bergagnini
Isabella A
IA
Kolakowski
Patricia
P
Edwards
Barbara
B
Smith
Miriam A
MA
D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage*; D053626:Atovaquone / Q000008:administration & dosage*; D018890:Chemoprevention / Q000706:statistics & numerical data; D004196:Disease Outbreaks / Q000517:prevention & control; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D019353:Endemic Diseases / Q000517:prevention & control; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D002727:Proguanil / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D014195:Travel; D014481:United States; D055815:Young Adult
D000962:Antimalarials; D004338:Drug Combinations; C109496:atovaquone, proguanil drug combination; D002727:Proguanil; D053626:Atovaquone